Publications by authors named "Edouard R Martin"
Introduction: Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis.
Methods: SIERRAS was a phase 3, randomized, open-label, active-controlled study enrolled adults on dialysis for end-stage kidney disease receiving erythropoiesis-stimulating agents for anemia.
Article Synopsis
- Vadadustat is an oral medication being tested to treat anemia in patients with chronic kidney disease (CKD), particularly those in stages 3 and 4, as current treatment options are limited.
- A phase 2a clinical trial involved 93 adults who took varying doses of vadadustat or a placebo for 6 weeks, with results showing that vadadustat significantly increased hemoglobin levels compared to the placebo.
- While vadadustat improved iron metrics and did not significantly increase adverse effects, the study had limitations such as a small sample size and a short duration, leading to further phase 3 trials in more patients.
Background: Iron-deficiency anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) frequently requires parenteral iron replacement, but existing therapies often require multiple administrations. We evaluated the efficacy and cardiovascular safety of ferric carboxymaltose (FCM), a non-dextran parenteral iron permitting large single-dose infusions, versus iron sucrose in patients with iron-deficiency anemia and NDD-CKD.
Methods: A total of 2584 participants were randomized to two doses of FCM 750 mg in one week, or iron sucrose 200 mg administered in up to five infusions in 14 days.
Background: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. The primary objective of this phase 2 dose-finding study was to determine the once-monthly peginesatide dosing strategy that would maintain hemoglobin within ±1.0 g/dL of baseline values after conversion from epoetin alfa; the safety of peginesatide was evaluated concurrently.
View Article and Find Full Text PDF